Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy
Bo Zhu,Liming Tang,Shuyang Chen,Chengqian Yin,Shiguang Peng,Xin Li,Tongzheng Liu,Wei Liu,Changpeng Han,Lukasz Stawski,Zhi-Xiang Xu,Guangbiao Zhou,Xiang Chen,Xiumei Gao,Colin R. Goding,Nan Xu,Rutao Cui,Peng Cao
DOI: https://doi.org/10.1038/s41388-018-0314-0
IF: 8.756
2018-05-22
Oncogene
Abstract:Programmed cell death ligand 1 (PD-L1) interacts with programmed cell death protein-1 (PD-1) as an immune checkpoint. Reactivating the immune response by inhibiting PD-L1 using therapeutic antibodies provides substantial clinical benefits in many, though not all, melanoma patients. However, transcriptional suppression of PD-L1 expression as an alternative therapeutic anti-melanoma strategy has not been exploited. Here we provide biochemical evidence demonstrating that ultraviolet radiation (UVR) induction of PD-L1 in skin is directly controlled by nuclear factor E2-related transcription factor 2 (NRF2). Depletion of NRF2 significantly induces tumor infiltration by both CD8+ and CD4+ T cells to suppress melanoma progression, and combining NRF2 inhibition with anti-PD-1 treatment enhanced its anti-tumor function. Our studies identify a critical and targetable PD-L1 upstream regulator and provide an alternative strategy to inhibit the PD-1/PD-L1 signaling in melanoma treatment.
oncology,genetics & heredity,biochemistry & molecular biology,cell biology